This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendHeadlinesOptions ChainTrendsBuy This Stock SVA vs. OGN, APLS, XENE, AMRX, MIRM, ARWR, NAMS, KNSA, GMTX, and LGNDShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Kiniksa Pharmaceuticals (KNSA), Gemini Therapeutics (GMTX), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry. Sinovac Biotech vs. Its Competitors Organon & Co. Apellis Pharmaceuticals Xenon Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals NewAmsterdam Pharma Kiniksa Pharmaceuticals Gemini Therapeutics Ligand Pharmaceuticals Organon & Co. (NYSE:OGN) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Does the MarketBeat Community believe in OGN or SVA? Sinovac Biotech received 237 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.99% of users gave Sinovac Biotech an outperform vote while only 34.48% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes2034.48% Underperform Votes3865.52% Sinovac BiotechOutperform Votes25767.99% Underperform Votes12132.01% Do analysts recommend OGN or SVA? Organon & Co. presently has a consensus price target of $18.00, suggesting a potential upside of 79.55%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities analysts clearly believe Organon & Co. is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, OGN or SVA? Organon & Co. has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Is OGN or SVA more profitable? Organon & Co. has a net margin of 13.49% compared to Sinovac Biotech's net margin of 0.00%. Organon & Co.'s return on equity of 431.62% beat Sinovac Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.13.49% 431.62% 8.03% Sinovac Biotech N/A N/A N/A Do institutionals & insiders believe in OGN or SVA? 77.4% of Organon & Co. shares are held by institutional investors. 2.0% of Organon & Co. shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor OGN or SVA? In the previous week, Organon & Co. had 33 more articles in the media than Sinovac Biotech. MarketBeat recorded 39 mentions for Organon & Co. and 6 mentions for Sinovac Biotech. Organon & Co.'s average media sentiment score of 0.05 beat Sinovac Biotech's score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 2 Very Positive mention(s) 2 Positive mention(s) 32 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Sinovac Biotech 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, OGN or SVA? Organon & Co. has higher revenue and earnings than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.29B0.41$864M$2.883.48Sinovac Biotech$448.27M1.44-$99.92MN/AN/A SummaryOrganon & Co. beats Sinovac Biotech on 13 of the 17 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.67M$6.88B$5.57B$8.51BDividend YieldN/A2.49%5.27%4.16%P/E RatioN/A8.4626.7519.65Price / Sales1.44262.48404.17152.19Price / Cash38.9565.8538.2534.64Price / Book0.056.526.964.59Net Income-$99.92M$143.26M$3.23B$248.23M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261News CoverageHigh Trading VolumeOGNOrganon & Co.4.7787 of 5 stars$9.76+2.1%$18.00+84.4%-50.9%$2.54B$6.29B2.9310,000Trending NewsAPLSApellis Pharmaceuticals4.7601 of 5 stars$19.39+0.6%$40.05+106.6%-55.2%$2.44B$775.84M-9.55770Positive NewsAnalyst RevisionXENEXenon Pharmaceuticals3.6624 of 5 stars$31.45-0.6%$54.82+74.3%-12.1%$2.41B$7.50M-11.15210Options VolumeAnalyst RevisionAMRXAmneal Pharmaceuticals3.5312 of 5 stars$7.61-0.1%$11.60+52.4%+12.5%$2.39B$2.83B-11.197,600MIRMMirum Pharmaceuticals3.2192 of 5 stars$47.05+1.4%$60.73+29.1%+91.5%$2.33B$379.25M-23.29140Analyst RevisionARWRArrowhead Pharmaceuticals3.7079 of 5 stars$16.57-1.4%$43.71+163.8%-39.1%$2.29B$545.21M-3.21400Analyst UpgradeAnalyst RevisionNAMSNewAmsterdam Pharma2.9609 of 5 stars$20.16+0.1%$42.86+112.6%+5.3%$2.26B$47.14M-10.724Positive NewsAnalyst ForecastAnalyst RevisionKNSAKiniksa Pharmaceuticals3.2373 of 5 stars$30.33+0.3%$38.80+27.9%+50.8%$2.21B$481.17M-216.63220Analyst UpgradeInsider TradeGMTXGemini TherapeuticsN/A$50.02+4.2%N/A+37.2%$2.17BN/A-50.0230News CoverageLGNDLigand Pharmaceuticals4.3856 of 5 stars$109.48+3.3%$146.14+33.5%+40.5%$2.11B$181.49M43.6280News Coverage Related Companies and Tools Related Companies OGN Alternatives APLS Alternatives XENE Alternatives AMRX Alternatives MIRM Alternatives ARWR Alternatives NAMS Alternatives KNSA Alternatives GMTX Alternatives LGND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SVA Stock Free SVA Stock Alerts